Edward J. Ludwig, a director at Boston Scientific Corp (NYSE:BSX), has sold shares in the company, according to a recent SEC filing. Ludwig sold 4,877 shares of common stock at an average price of $91.63 per share, totaling approximately $446,901. Following this transaction, Ludwig holds 39,398 shares of the medical device manufacturer.
This sale comes as Boston Scientific continues to expand its portfolio in the surgical and medical instruments sector, headquartered in Marlborough, Massachusetts.
"In other recent news, Boston Scientific has announced the approval of its 2025 Annual Bonus Plan and two new performance share programs. These initiatives are designed to align executive compensation with company performance metrics and shareholder interests. The company also revealed its plans to acquire Cortex, a firm with a unique cardiac mapping system, OptiMap. This acquisition has been perceived positively by analysts at TD Cowen, who maintain a Buy rating on Boston Scientific.
In addition, the company has resumed its AVANT GUARD clinical trial, which focuses on a new treatment option for patients with persistent atrial fibrillation. Boston Scientific's cardiology business has been growing robustly, with a 27% increase in the U.S. and 18% internationally, driven by strong performances in the ICTx and EP business sectors, and the WATCHMAN franchise.
Moreover, the company has received recent product approvals, including the FARAVIEW mapping software and FARAWAVE NAV catheter. Despite the ACURATE IDE trial not meeting its primary endpoint, the ACURATE platform has shown a 20% revenue growth in EMEA, surpassing $200 million. These recent developments highlight Boston Scientific's commitment to innovation and growth in the cardiology market."
InvestingPro Insights
As Boston Scientific Corp (NYSE:BSX) continues to expand its portfolio, recent InvestingPro data sheds light on the company's financial performance and market position. The company's revenue growth of 15.66% over the last twelve months, coupled with a robust quarterly revenue growth of 19.34% in Q3 2024, underscores its strong market presence and expansion efforts.
InvestingPro Tips highlight that Boston Scientific is a prominent player in the Healthcare Equipment & Supplies industry, with 20 analysts revising their earnings upwards for the upcoming period. This positive sentiment aligns with the company's recent portfolio expansion and could potentially explain the director's decision to sell shares, possibly to realize gains from the company's strong performance.
The stock's impressive performance is further evidenced by its 62.37% price return over the past year, trading near its 52-week high. However, investors should note that BSX is trading at a high P/E ratio of 73.52, which may indicate that the stock is priced at a premium relative to its earnings.
For those interested in a deeper analysis, InvestingPro offers 17 additional tips for Boston Scientific, providing a comprehensive view of the company's financial health and market position. These insights can be valuable for investors looking to make informed decisions in the dynamic healthcare equipment sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.